NGS-based MRD (clonoSEQ and molecular MRD)
Sequencing the unique genetic barcode of a patient's leukaemia to find one cancer cell in a million.
clonoSEQ (Adaptive Biotechnologies) tracks clonal IGH/TCR rearrangements at 10^-6 and is FDA-cleared for ALL, myeloma, and CLL. In AML, quantitative PCR of NPM1 or core-binding-factor fusion transcripts and error-corrected NGS of persistent mutations (excluding DNMT3A/TET2/ASXL1) define molecular MRD per ELN 2021. MRD status now drives transplant decisions in AML, blinatumomab use in ALL, and fixed-duration versus continuous therapy debates in CLL.
How it works
The assay deep-sequences a patient-specific clonotype or mutation with error correction.
- 10^-5 to 10^-6 sensitivity
- Blood-based monitoring in many settings
- Requires a baseline sample to identify the clone
- Persisting pre-leukaemic clones (CHIP) confound AML MRD
Latest papers
topQuery for this technology: (TITLE:"NGS-based MRD" OR ABSTRACT:"NGS-based MRD" OR TITLE:"clonoSEQ and molecular MRD" OR ABSTRACT:"clonoSEQ and molecular MRD") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about NGS-based MRD (clonoSEQ and molecular MRD), not a curated reading list.
Pages like this
not linked directly; found by shared links- TechnologyMultiparameter flow cytometry MRD
Shares MRD-negative complete remission, Myelodysplastic syndromes / neoplasms (MDS), Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD).
- CollectionLeukemia & Lymphoma Society (LLS)
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Myelodysplastic syndromes / neoplasms (MDS), Chronic lymphocytic leukaemia, Multiple myeloma.
- InstitutionSylvester Comprehensive Cancer Center, University of Miami
Shares Myelodysplastic syndromes / neoplasms (MDS), Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Multiple myeloma.
- TechnologyAllogeneic stem cell transplantation
Shares MRD-guided transplant decisions in intermediate-risk AML, Transplant-free Ph-positive ALL for MRD-negative adults, MRD-negative complete remission, Myeloproliferative neoplasms (PV, ET, myelofibrosis).
- InstitutionGIMEMA
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, MRD / molecular residual disease testing, Multiple myeloma.
- CompanyForesight Diagnostics
Shares Reference materials and open proficiency testing for residual disease tests, Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing.
- TermELN 2022 risk classification
Shares MRD-guided transplant decisions in intermediate-risk AML, Myeloproliferative neoplasms (PV, ET, myelofibrosis), Myelodysplastic syndromes / neoplasms (MDS), Acute myeloid leukaemia.
- TermFlow cytometry (immunophenotyping)
Shares Minimal / molecular residual disease (MRD), Chronic lymphocytic leukaemia, Multiple myeloma, Acute lymphoblastic leukaemia.